Mesothelioma treatment has traditionally relied on chemotherapy, which can help slow the cancer but may not work as well in more advanced cases.
Immunotherapy for mesothelioma uses cutting-edge drugs to help the body’s own immune system better recognize and fight cancer. This approach can extend survival and help keep the cancer under control for longer periods, even for patients who previously had few options.
A 2026 review found that immunotherapy, especially nivolumab plus ipilimumab, can help patients with pleural mesothelioma live longer and keep their cancer controlled longer compared with chemotherapy.
For those living with mesothelioma, this research represents hope that new treatments are giving more patients a chance to live longer, fuller lives.
What Did the Latest Mesothelioma Immunotherapy Research Find?
A new review published in Therapeutic Advances in Medical Oncology shows that the immune checkpoint inhibitors nivolumab (Opdivo®) and ipilimumab (Yervoy®) extended survival to about 18 months in patients with pleural mesothelioma.
On the other hand, traditional chemotherapy with cisplatin and pemetrexed (Alimta®) offered a more limited benefit, with a median survival of about 12 months and a response rate of roughly 41%.
Doctors group mesothelioma into different cell types, including epithelioid, sarcomatoid, and biphasic. Epithelioid is the most common and tends to respond better to treatment. Sarcomatoid is more aggressive and harder to treat. Biphasic is a mix of both. These differences matter because they can affect how well immunotherapy for mesothelioma works.
Here are key takeaways from the 2026 report:
- New standard first treatment: The combination of Opdivo and Yervoy is now an approved standard treatment for inoperable pleural mesothelioma.
- Extended survival: Median overall survival increased from around 12 months with chemotherapy to 18.1 months with immunotherapy.
- Longer disease control: Some patients have their cancer shrink or stop growing for longer periods of time, which is known as a treatment response.
- Benefit across cell types: Both epithelioid and non-epithelioid cell types had improved survival compared with chemotherapy alone.
- Improved survival rates: About 14% of patients treated with dual immunotherapy were alive at 5 years, compared to 6% with chemotherapy.
- Better outcomes for aggressive cell types: In more aggressive forms of mesothelioma, a higher percentage of patients were alive after 5 years with immunotherapy than with chemotherapy (12% vs. 1%).
- Tolerable side effects: Immunotherapy side effects can usually be managed with medical care, though immune-related side effects need close monitoring.
- Ongoing research: Clinical trials for mesothelioma are studying ways to predict who will benefit most from immunotherapy and testing different drug combinations with other treatments.
- Real-world impact: Evidence outside of clinical trials confirms that dual immunotherapy extends survival and can improve quality of life.
Mesothelioma is still a serious disease, but immunotherapy is giving patients more time and better control over their cancer than was possible in the past. While it doesn’t work for everyone, it represents an important step forward and can help some people extend their life expectancy.
Find out if immunotherapy is right for you. Get connected with a top mesothelioma specialist using our Free Doctor Match service.
Nivolumab + Ipilimumab Extends Mesothelioma Survival Rates
Before immunotherapy, treatment options for mesothelioma were limited. Standard chemotherapy drugs typically helped for a time, but most patients lived about a year on average, and long-term survival was uncommon.
Mesothelioma immunotherapy is beginning to change that. For some patients, it can help the immune system keep the cancer under control for longer, turning what was once a short-term outcome into something more lasting.
With dual immunotherapy, the median survival increased to 18.1 months, and roughly 14% of patients were still alive 5 years later, compared with only about 6% for chemotherapy. For patients with non-epithelioid mesothelioma, immunotherapy improved 5-year survival from around 1% to 12%.
“Today, the biggest leap forward is combination immunotherapy, specifically ipilimumab plus nivolumab, which has become a first-line option… This benefit is especially pronounced for patients with non-epithelioid mesothelioma, nearly doubling survival compared to chemotherapy.”
While not every patient responds to immunotherapy, these results are the most significant shift in mesothelioma treatment in decades, giving hope where previously there was very little.
Download our Free Mesothelioma Immunotherapy Guide to learn about benefits, side effects, and what to expect during treatment.
Find Mesothelioma Immunotherapy Near You
Mesothelioma Hope’s team of registered nurses, oncology nurse navigators, and Patient Advocates can help patients and families understand their diagnosis, treatment options, and how to manage any side effects.
If you were recently diagnosed with mesothelioma, we can help you understand your symptoms, find a doctor near you, and start treatment. If you’re already getting treated, we can help you manage your side effects, consider other options, and find additional support for your family.
We can also help families pursue financial compensation to help manage the costs of treatment, traveling to specialists, and everyday expenses that add up throughout their mesothelioma journey.
Contact Mesothelioma Hope now or call (866) 608-8933 to speak with a member of our team. We’re available 24/7 to answer your questions and provide the guidance you need.
